Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

872
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
872
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

3.4K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.4K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

778
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
778
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

780
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
780
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

730
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
730
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

3.4K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional characterization of <b><i>KCNA5</i></b> gene variants linked to pulmonary arterial hypertension.

The European respiratory journal·2026
Same author

Enhanced fatty acid availability rewires fibroblasts metabolism and decreases collagen deposition in lung fibrosis.

Cellular and molecular life sciences : CMLS·2026
Same author

Selective MIF Enolase Inhibitor TE-91 Regulates M1 Polarization and Associated Metabolic Reprogramming.

Antioxidants (Basel, Switzerland)·2026
Same author

Transcriptional landscape of pulmonary artery endothelium reveals subpopulation- and disease-specific remodeling signatures.

Communications biology·2026
Same author

Prognostic Value of Exercise Testing in Patients with Liver Cirrhosis.

Diagnostics (Basel, Switzerland)·2026
Same author

Noninvasive mean pulmonary arterial pressure/oxygen uptake slope as a predictor of pulmonary exercise haemodynamics and outcome.

ERJ open research·2026

Related Experiment Video

Updated: Oct 26, 2025

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.2K

Low oxygen levels decrease adaptive immune responses and ameliorate experimental asthma in mice.

Mathias Hochgerner1, Eva M Sturm2, Diana Schnoegl1

  • 1Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.

Allergy
|July 26, 2021
PubMed
Summary
This summary is machine-generated.

High-altitude therapy, or hypoxia, reduces allergic asthma symptoms by suppressing immune responses. This occurs by interfering with antigen-presenting cells and their interaction with T-cells, leading to an unresponsive immune phenotype.

Keywords:
MHC-IIallergyasthmadendritic cellshypoxia

More Related Videos

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

22.8K
Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury
14:48

Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury

Published on: March 21, 2021

5.3K

Related Experiment Videos

Last Updated: Oct 26, 2025

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.2K
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

22.8K
Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury
14:48

Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury

Published on: March 21, 2021

5.3K

Area of Science:

  • Immunology
  • Respiratory Medicine
  • Environmental Physiology

Background:

  • High-altitude therapy is a recognized add-on treatment for allergic asthma.
  • The precise mechanisms behind its therapeutic effects remain largely unknown.
  • A novel in vivo mouse model was employed to explore these mechanisms.

Purpose of the Study:

  • To investigate the therapeutic effects of high-altitude therapy on allergic asthma.
  • To elucidate the underlying immunological mechanisms of high-altitude therapy in asthma.

Main Methods:

  • Mice were exposed to house dust mite (HDM) extract and either hypoxia (10% oxygen) or room air.
  • Asthma severity was evaluated by measuring airway hyper-responsiveness, mucus production, and inflammatory cell infiltration.
  • Immune cells from mice and allergic patients were stimulated in vitro under hypoxic and normoxic conditions to analyze adaptive immune responses.

Main Results:

  • Hypoxia significantly ameliorated asthma symptoms, including reduced mucus hypersecretion and airway hyper-responsiveness.
  • The beneficial effects were linked to decreased activation of antigen-presenting cells (APCs), reduced inflammatory cell infiltration, and lower cytokine secretion.
  • In vitro, hypoxia suppressed HDM-induced adaptive immune responses, primarily by impairing APC differentiation and APC/T-cell communication.

Conclusions:

  • Hypoxia ameliorates allergic asthma by reducing the T-helper 2 (Th2) immune response.
  • High-altitude therapy impacts allergic asthma by disrupting antigen-presenting cell (APC) function and APC-T-cell crosstalk.
  • Hypoxia induces an unresponsive phenotype in APCs, contributing to asthma symptom relief.